MEG
UTHR icon

Millstone Evans Group’s United Therapeutics UTHR Stock Holding History

Millstone Evans Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Hold
190
– – 0.06% 239
2026
Q1 		$113K Hold
190
– – 0.07% 217
2025
Q4 		$92.6K Hold
190
– – 0.05% 243
2025
Q3 		$79.7K Hold
190
– – 0.05% 240
2025
Q2 		$54.6K Hold
190
– – 0.04% 283
2025
Q1 		$58.6K Hold
190
– – 0.04% 269
2024
Q4 		$67K Buy
+190
New +$69.8K 0.05% 242

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Millstone Evans Group's UTHR Position: Q2 2026 in Review

Millstone Evans Group held its United Therapeutics (UTHR) position steady in Q2 2026 at 190 shares worth $103K. The position accounts for 0.06% of the portfolio, ranked #239.

Millstone Evans Group first reported a position in UTHR in Q4 2024 and has held it in 7 quarters since. The position peaked at $113K in Q1 2026. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Millstone Evans Group held 190 shares of United Therapeutics worth $103K as of Q2 2026.
  • Millstone Evans Group left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up 0.06% of Millstone Evans Group's portfolio in Q2 2026, its #239 holding.
  • Millstone Evans Group first reported a position in United Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Millstone Evans Group's United Therapeutics position peaked at $113K in Q1 2026.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Millstone Evans Group's 13F filing for Q2 2026, filed 11 Aug 2026.